Interestingly, we have noted in a separate study that downregulation of Mcm2 and geminin is linked to hormonal blockade and clinical response, suggesting that although these biomarkers appear to be of limited value for prognostication, they may have potential as predictors of therapeutic response in breast cancer (Shetty et al, unpublished data). Here, MCM2 is linked to breast carcinoma.